Concepedia

Author

George Thom

AstraZeneca (United Kingdom)ORCID

Also Known As

G Thom, G. Thom, GEORGE THOM, George THOM, George Thom

32

Publications

1K

Citations

16

H-Index

56

Concepts

All Affiliations

AstraZeneca (United Kingdom)National Research Council CanadaRecombinant Antibody Technology (United Kingdom)AstraZeneca (Sweden)University of Cambridge
GT

About

George Thom is an author at AstraZeneca (United Kingdom) specializing in medicine, immunology, and antibody engineering.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

229

2

Allergy

3

3

105

3

Engineering

2

2

56

4

Natural Sciences

2

2

108

5

Health Sciences

1

1

39

George Thom

×

17

Publications

957

Citations

16

H-Index

YearCitations

A conserved role of a DEAD box helicase in mRNA masking

Nicola Minshall, George Thom, Nancy Standart

RNA

2001

143

Modelling the endothelial blood-CNS barriers: a method for the production of robust in vitromodels of the rat blood-brain barrier and blood-spinal cord barrier

Paul Watson, Judy Paterson, George Thom,

BMC Neuroscience

2013

95

Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier <i>in vitro</i> is dependent on its binding affinity

Arsalan S. Haqqani, George Thom, Matthew Burrell,

Journal of Neurochemistry

2018

89

Brain penetration, target engagement, and disposition of the blood‐brain barrier‐crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1

Carl I. Webster, Nadia L. Caram‐Salas, Arsalan S. Haqqani,

The FASEB Journal

2016

80

Probing a protein–protein interaction by <i>in vitro</i> evolution

George Thom, Alexis C. Cockroft, Andrew Buchanan,

Proceedings of the National Academy of Sciences

2006

79

Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26

George Thom, Matthew Burrell, Arsalan S. Haqqani,

Molecular Pharmaceutics

2018

69

Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti–transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity

Carl I. Webster, Jon P. Hatcher, Matthew Burrell,

Pain

2016

67

Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy

Suzan M. Hammond, Frank Abendroth, Larissa Goli,

JCI Insight

2022

54

In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus

Yulia Vugmeyster, Heath Guay, Pamela Szklut,

mAbs

2010

49

Antibodies binding the head domain of P2X4 inhibit channel function and reverse neuropathic pain

Wendy A. Williams, John E. Linley, Clare A. Jones,

Pain

2019

42

Page 1